Exclusive: Sanofi stops enrolling COVID-19 patients in hydroxychloroquine trials amid safety concerns
Published
Sanofi has temporarily stopped recruiting new COVID-19 patients for its two clinical trials on hydroxychloroquine and will not supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up, it said on Friday.
Full Article